# Hims & Hers Health

Type: Company (HIMS)

Source: Legal & RegTech Intelligence Brief — https://getlegalbrief.com/entity/hims-hers-health
Canonical HTML page: https://getlegalbrief.com/entity/hims-hers-health

## Timeline

- **2026-03-09**: Settlement & Collaboration — Hims & Hers and Novo Nordisk announce the end of litigation and the start of a commercial partnership.
- **2026-03**: Settlement Reached — Hims & Hers agrees to stop selling compounded GLP-1s to resolve legal disputes.
- **2025-10-15**: Supply Stabilization — FDA indicates that semaglutide shortages are easing, increasing legal pressure on compounders.
- **2025**: Litigation Surge — Novo Nordisk and Eli Lilly file multiple lawsuits against compounding pharmacies and telehealth firms.
- **2024**: FDA Shortage Updates — FDA begins removing specific GLP-1 dosages from the national shortage list.
- **2024-05-20**: Hims & Hers GLP-1 Launch — Hims & Hers announces the launch of compounded GLP-1 injections at a significant discount to brand names.
- **2024-05**: HIMS Launches GLP-1s — Hims & Hers enters the weight-loss market with compounded GLP-1 offerings.
- **2023-06-01**: Litigation Wave Begins — Novo Nordisk starts filing lawsuits against medical spas and pharmacies over compounded semaglutide.

## Recent coverage (2 stories)

### Hims & Hers Health to Halt Compounded GLP-1 Sales in Landmark Settlement
2026-03-09 17:30:26 · Sentiment: Negative · Impact: 6/10 · Sources: 2

Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in the telehealth landscape. This move follows intense regulatory scrutiny and litigation regarding the legality of compounding patented weight-loss drugs during supply shortages.
Full story: https://getlegalbrief.com/story/hims-hers-glp1-settlement-regulation

### Hims & Hers and Novo Nordisk Settle GLP-1 Litigation, Pivot to Collaboration
2026-03-09 17:29:52 · Sentiment: Positive · Impact: 6/10 · Sources: 5

Hims & Hers Health and Novo Nordisk have reached a settlement to end their legal dispute over compounded weight loss medications. The agreement transitions the relationship from adversarial litigation to a strategic collaboration, potentially reshaping the telehealth distribution model for GLP-1 drugs.
Full story: https://getlegalbrief.com/story/hims-hers-novo-nordisk-glp1-settlement-collaboration

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getlegalbrief.com/guides/methodology for the full editorial methodology.